Clinical Trial Update: Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update reports on discontinuing infliximab therapy in Crohn's disease patients who are in sustained complete remission.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Infliximab (infliximab)

Snippet

Sponsor: Copenhagen University Hospital at Herlev | Conditions: Crohn Disease | Phase 4 | Status: COMPLETED